1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Huang, K. Xu, B. Hu, S.Q. Chu, Y.C. Hua, Q.X. Whittaker, J. Nakagawa, S.H. De Meyts, P. Katsoyannis, P.G. Weiss, M.A. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C4 H9 N O2 103.120 n ALPHA-AMINOBUTYRIC ACID L-peptide linking C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking UK J.Mol.Biol. JMOBAK 0070 0022-2836 341 529 550 10.1016/j.jmb.2004.05.023 15276842 How Insulin Binds: the B-Chain alpha-Helix Contacts the L1 beta-Helix of the Insulin Receptor. 2004 US Biochemistry BICHAW 0033 0006-2960 39 15826 15835 10.1021/bi001802+ 11123908 MUTATIONAL ANALYSIS OF INVARIANT VALINE B12 IN INSULIN: IMPLICATION FOR RECEPTOR BINDING 2000 US J.Biol.Chem. JBCHA3 0071 0021-9258 272 12978 12983 10.1074/jbc.272.20.12978 9148904 ALANINE SCANNING MUTAGENESIS OF INSULIN 1997 AT BIOCHEM.MOL.BIOL.INT. BMBIES 2062 1039-9712 39 1245 1254 8876979 STUDIES ON RECEPTOR BINDING SITE OF INSULIN: THE HYDROPHOBIC B12VALCAN BE SUBSTITUTED BY HYDROPHILIC THR 1996 US Biochemistry BICHAW 0033 0006-2960 32 2631 2635 8448120 STERIC REQUIRMENTS AT POSITION B12 FOR HIGH BIOLOGICAL ACTIVITY IN INSULIN 1993 DK INT.J.PEPT.PROTEIN RES. IJPPC3 0215 0367-8377 17 243 255 7014485 [12-ASPARAGINE-B] HUMAN INSULIN. AN ANALOGUE WITH MODIFICATION IN THEHYDROPHOBIC CORE OF INSULIN 1981 10.2210/pdb1t1q/pdb pdb_00001t1q 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M x-ray 1 1.0 2383.698 insulin INSULIN A CHAIN HIS-B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS-B29-PRO 1 syn polymer 3396.868 Insulin INSULIN B CHAIN 1 syn polymer no no GIVEQCCTSICSLYQLENYCN GIVEQCCTSICSLYQLENYCN A polypeptide(L) no yes FVNQHLCGSDL(ABA)EALYLVCGERGFFYTKPT FVNQHLCGSDLAEALYLVCGERGFFYTKPT B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n database_2 struct_conn struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Database references Database references Derived calculations 1 0 2004-08-10 1 1 2008-04-30 1 2 2011-07-13 1 3 2012-03-28 1 4 2021-10-27 _database_2.pdbx_DOI _database_2.pdbx_database_accession _struct_conn.pdbx_leaving_atom_flag _struct_ref_seq_dif.details PARENT MOLECULE OF THIS DEPOSITION, CONTAINS THREE SUBSTITUTIONS ALA-B12-DKP-INSULIN THR-B12-DKP-INSULIN RCSB Y RCSB 2004-04-16 REL REL THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF THE PEPTIDE IS NATURALLY FOUND IN HOMO SAPIENS(HUMAN) sample THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF THE PEPTIDE IS NATURALLY FOUND IN HOMO SAPIENS(HUMAN) sample This structure was determined by using standard 2D homonuclear techniques structures with the lowest energy 50 15 2D NOESY 2D TOCSY DQF-COSY 7.0 ambient 298 K 7.6 ambient 305 K the structures are based on a total of 590 restraints: 527 are NOE-derived distance constraints, 39 are dihedral angle restraints, 24 are hydrogen bond restraints. DISTANCE GEOMETRY AND SIMULATED ANNEALING 1 closest to the average 1.2 mM ABA-B12-DKP-insulin, 90% H2O, 10% D2O 90% H2O/10% D2O 1.2 mM ABA-B12-DKP-insulin,100% D2O 100% D2O Molecular Simulations INC. structure solution DGII INSIGHTII 2000 Brunger refinement X-PLOR 3.85 600 Varian INOVA 800 Bruker DRX GLY 1 n 1 GLY 1 A ILE 2 n 2 ILE 2 A VAL 3 n 3 VAL 3 A GLU 4 n 4 GLU 4 A GLN 5 n 5 GLN 5 A CYS 6 n 6 CYS 6 A CYS 7 n 7 CYS 7 A THR 8 n 8 THR 8 A SER 9 n 9 SER 9 A ILE 10 n 10 ILE 10 A CYS 11 n 11 CYS 11 A SER 12 n 12 SER 12 A LEU 13 n 13 LEU 13 A TYR 14 n 14 TYR 14 A GLN 15 n 15 GLN 15 A LEU 16 n 16 LEU 16 A GLU 17 n 17 GLU 17 A ASN 18 n 18 ASN 18 A TYR 19 n 19 TYR 19 A CYS 20 n 20 CYS 20 A ASN 21 n 21 ASN 21 A PHE 1 n 1 PHE 1 B VAL 2 n 2 VAL 2 B ASN 3 n 3 ASN 3 B GLN 4 n 4 GLN 4 B HIS 5 n 5 HIS 5 B LEU 6 n 6 LEU 6 B CYS 7 n 7 CYS 7 B GLY 8 n 8 GLY 8 B SER 9 n 9 SER 9 B ASP 10 n 10 ASP 10 B LEU 11 n 11 LEU 11 B ABA 12 n 12 ABA 12 B GLU 13 n 13 GLU 13 B ALA 14 n 14 ALA 14 B LEU 15 n 15 LEU 15 B TYR 16 n 16 TYR 16 B LEU 17 n 17 LEU 17 B VAL 18 n 18 VAL 18 B CYS 19 n 19 CYS 19 B GLY 20 n 20 GLY 20 B GLU 21 n 21 GLU 21 B ARG 22 n 22 ARG 22 B GLY 23 n 23 GLY 23 B PHE 24 n 24 PHE 24 B PHE 25 n 25 PHE 25 B TYR 26 n 26 TYR 26 B THR 27 n 27 THR 27 B LYS 28 n 28 LYS 28 B PRO 29 n 29 PRO 29 B THR 30 n 30 THR 30 B author_defined_assembly 2 dimeric B ABA 12 ALPHA-AMINOBUTYRIC ACID B ABA 12 ALA 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A B H O ASN GLY 21 23 1.48 1 B B O H GLY LEU 8 11 1.49 1 B B O H GLU LEU 13 17 1.50 2 A B H O ASN GLY 21 23 1.46 2 B B O H GLY LEU 8 11 1.47 2 B B O H CYS GLU 19 21 1.58 3 A B H O ASN GLY 21 23 1.44 3 B B O H GLU LEU 13 17 1.52 4 A B H O ASN GLY 21 23 1.49 4 A A O H GLN SER 5 9 1.56 4 B B O H GLU LEU 13 17 1.59 5 A A O H SER GLN 12 15 1.58 6 A B H O ASN GLY 21 23 1.47 6 B B O H ALA VAL 14 18 1.51 6 B B O H GLU LEU 13 17 1.59 7 A B H O ASN GLY 21 23 1.48 7 B B O H GLU LEU 13 17 1.50 7 B B O H GLY LEU 8 11 1.56 8 B B O H GLY LEU 8 11 1.45 8 A B H O ASN GLY 21 23 1.47 8 B B O H GLU LEU 13 17 1.51 9 A B H O ASN GLY 21 23 1.51 9 B B O H GLY GLY 20 23 1.52 9 B B O H GLU LEU 13 17 1.53 9 B B O H GLY LEU 8 11 1.54 10 B B O H GLY LEU 8 11 1.48 10 A B H O ASN GLY 21 23 1.49 10 B B O H GLU LEU 13 17 1.55 11 A B H O ASN GLY 21 23 1.47 11 B B O H ALA VAL 14 18 1.57 12 B B O H GLY LEU 8 11 1.56 12 B B O H GLU LEU 13 17 1.56 13 A B H O ASN GLY 21 23 1.47 13 B B O H GLY LEU 8 11 1.47 13 B B O H GLU LEU 13 17 1.48 13 B B O H CYS GLU 19 21 1.56 13 A A O H SER GLN 12 15 1.58 14 A B H O ASN GLY 21 23 1.48 14 B B O H GLU LEU 13 17 1.53 15 A B H O ASN GLY 21 23 1.47 15 B B O H GLY LEU 8 11 1.51 15 B B O H GLU LEU 13 17 1.53 1 B ARG 22 0.312 SIDE CHAIN 2 B ARG 22 0.213 SIDE CHAIN 4 B ARG 22 0.272 SIDE CHAIN 5 B ARG 22 0.314 SIDE CHAIN 6 B ARG 22 0.295 SIDE CHAIN 7 B ARG 22 0.236 SIDE CHAIN 8 B ARG 22 0.206 SIDE CHAIN 9 B ARG 22 0.296 SIDE CHAIN 10 B ARG 22 0.239 SIDE CHAIN 11 B ARG 22 0.312 SIDE CHAIN 12 B ARG 22 0.311 SIDE CHAIN 13 B ARG 22 0.141 SIDE CHAIN 14 B ARG 22 0.174 SIDE CHAIN 15 B ARG 22 0.237 SIDE CHAIN 1 A LEU 13 -38.53 -28.43 1 B CYS 19 -116.03 -78.95 1 B LYS 28 61.48 116.73 1 B PRO 29 -77.42 -77.53 2 A LEU 13 -28.80 -40.06 2 B VAL 2 -86.11 -112.13 2 B CYS 7 -120.35 -80.64 2 B CYS 19 -116.97 -77.94 2 B LYS 28 170.66 79.71 3 A GLN 5 -102.86 -87.37 3 A THR 8 -89.79 30.08 3 A SER 9 164.35 -167.62 3 B VAL 2 -97.39 50.88 3 B ASN 3 -50.21 84.05 3 B CYS 19 -94.52 -61.10 3 B GLU 21 -65.40 87.77 3 B ARG 22 174.62 -35.39 3 B LYS 28 -163.84 89.37 4 A GLN 5 -101.07 -102.74 4 A SER 9 -120.26 -157.82 4 A LEU 13 -23.60 -56.97 4 B ASN 3 40.53 24.40 4 B CYS 19 -108.45 -73.91 5 A LEU 13 -27.04 -44.92 5 B ASN 3 39.52 47.12 5 B CYS 19 -131.63 -58.62 5 B PHE 24 -171.46 124.08 6 A GLN 5 -95.53 -75.94 6 A SER 9 -146.15 -156.50 6 B VAL 2 -100.25 -88.85 6 B ASN 3 -111.01 53.40 6 B LEU 6 -177.36 115.43 6 B GLU 13 -91.73 -60.93 6 B CYS 19 -130.78 -73.95 7 A VAL 3 -49.91 -16.99 7 A GLN 5 -99.84 -76.63 7 A SER 9 -118.89 -167.61 7 B VAL 2 -60.26 -103.50 7 B LEU 6 -119.06 -163.37 7 B CYS 7 -165.90 -86.68 7 B CYS 19 -128.47 -75.75 7 B LYS 28 -178.27 97.55 7 B PRO 29 -78.49 -160.79 8 A GLN 5 -97.16 -65.21 8 A CYS 7 -76.60 -85.36 8 A SER 9 -128.27 -167.88 8 A LEU 13 -39.23 -27.43 8 B VAL 2 -100.36 53.21 8 B ASN 3 -53.22 92.16 8 B CYS 7 -117.55 -98.51 8 B CYS 19 -130.31 -76.62 8 B TYR 26 -114.09 72.86 8 B LYS 28 -154.21 52.31 9 A CYS 7 -93.65 -61.98 9 B CYS 7 -126.62 -88.86 9 B CYS 19 -112.86 -77.53 9 B PRO 29 -78.39 -167.12 10 A THR 8 -68.19 -73.40 10 A LEU 13 -30.70 -34.73 10 B ASN 3 -26.99 87.75 10 B CYS 7 -119.28 -79.69 10 B CYS 19 -107.72 -75.76 10 B PHE 25 -100.41 -89.62 10 B TYR 26 99.90 73.44 10 B LYS 28 177.51 106.88 11 A SER 9 -109.79 -159.03 11 B VAL 2 -43.81 96.04 11 B ASN 3 -95.47 49.90 11 B LEU 6 -172.68 99.86 11 B CYS 19 -111.35 -76.40 11 B LYS 28 -163.08 60.62 12 A GLN 5 -101.14 -65.75 12 A LEU 13 -37.66 -28.99 12 B ASN 3 -47.19 94.70 12 B VAL 18 -102.33 -62.05 12 B PHE 25 -100.77 -90.41 12 B TYR 26 103.73 84.97 12 B THR 27 -60.41 -179.23 13 A GLN 5 -105.94 -79.56 13 A SER 9 -107.22 -163.73 13 A LEU 13 -37.07 -28.44 13 B CYS 7 -114.07 -84.96 13 B CYS 19 -111.30 -75.62 13 B LYS 28 -173.75 74.61 14 A GLN 5 -103.30 -75.80 14 A SER 9 -121.08 -164.03 14 A LEU 13 -32.86 -32.34 14 B ASN 3 58.82 17.59 14 B CYS 19 -129.21 -72.71 14 B LYS 28 74.94 69.39 15 B ASN 3 -56.04 83.39 15 B CYS 7 -130.17 -83.66 15 B CYS 19 -112.17 -78.24 15 B PHE 25 -100.47 -81.77 15 B TYR 26 89.67 92.84 NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES 1 N N 2 N N A SER 12 A SER 12 HELX_P A GLU 17 A GLU 17 1 1 6 B CYS 7 B CYS 7 HELX_P B CYS 19 B CYS 19 1 2 13 disulf 2.013 A CYS 6 A SG CYS 6 1_555 A CYS 11 A SG CYS 11 1_555 disulf 2.020 A CYS 7 A SG CYS 7 1_555 B CYS 7 B SG CYS 7 1_555 disulf 2.019 A CYS 20 A SG CYS 20 1_555 B CYS 19 B SG CYS 19 1_555 covale 1.303 both B LEU 11 B C LEU 11 1_555 B ABA 12 B N ABA 12 1_555 covale 1.309 both B ABA 12 B C ABA 12 1_555 B GLU 13 B N GLU 13 1_555 HORMONE/GROWTH FACTOR Aba-B12-DKP-insulin, protein unfolding, insulin receptor, receptor binding, HORMONE-GROWTH FACTOR COMPLEX INS_HUMAN UNP 1 1 P01308 GIVEQCCTSICSLYQLENYCN INS_HUMAN UNP 2 25 P01308 FVNQHLCGSHLVEALYLVCGERGFFYTPKT 1 21 1T1Q 1 21 P01308 A 1 1 21 25 54 1T1Q 1 30 P01308 B 2 1 30 2 HIS engineered mutation ASP 10 1T1Q B P01308 UNP 34 10 2 VAL engineered mutation ABA 12 1T1Q B P01308 UNP 36 12 2 PRO engineered mutation LYS 28 1T1Q B P01308 UNP 52 28 2 LYS engineered mutation PRO 29 1T1Q B P01308 UNP 53 29